Price$1.81-0.35 (-16.20%)
2026-05-212026-08-25
News · 26 weeks39+25%
2026-03-012026-08-23
Mix1190d
- Other5(45%)
- SEC Filings4(36%)
- Leadership1(9%)
- Analyst1(9%)
Latest news
25 items- PRAnnovis to Host Corporate Update Webinar on September 2, 2026MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones. Webinar details Date: Wednesday, September 2, 2026Time: 4:00 p.m. EDTPresenter: Maria Maccecchini, Ph.D., Founder, President, and CEORegistration link "Annovis is advancing acro
- SECSEC Form PRE 14A filed by Annovis Bio Inc.PRE 14A - Annovis Bio, Inc. (0001477845) (Filer)
- SECSEC Form 10-Q filed by Annovis Bio Inc.10-Q - Annovis Bio, Inc. (0001477845) (Filer)
- SECSEC Form SCHEDULE 13G filed by Annovis Bio Inc.SCHEDULE 13G - Annovis Bio, Inc. (0001477845) (Subject)
- PRAnnovis Provides Corporate Updates and Second Quarter 2026 Financial ResultsPivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT. MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and re
- SECSEC Form SCHEDULE 13G filed by Annovis Bio Inc.SCHEDULE 13G - Annovis Bio, Inc. (0001477845) (Subject)
- SECAnnovis Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Annovis Bio, Inc. (0001477845) (Filer)
- ANALYSTRoth Capital initiated coverage on Annovis Bio with a new price targetRoth Capital initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $8.00
- PRAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s DiseasePivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD. The trial enrolled 85
- PRAnnovis Appoints Cheng Fang, Ph.D., as Chief Scientific OfficerMALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interaction
- SECSEC Form 8-K filed by Annovis Bio Inc.8-K - Annovis Bio, Inc. (0001477845) (Filer)
- PRAnnovis Bio Regains NYSE Listing ComplianceMALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards. On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equi
- INSIDERDirector Hoffman Michael B bought $142,779 worth of shares (76,344 units at $1.87), increasing direct ownership by 2% to 3,364,883 units (SEC Form 4)4 - Annovis Bio, Inc. (0001477845) (Issuer)
- SECAnnovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Annovis Bio, Inc. (0001477845) (Filer)
- SECSEC Form 424B5 filed by Annovis Bio Inc.424B5 - Annovis Bio, Inc. (0001477845) (Filer)
- PRAnnovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying WarrantsMALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock,
- SECSEC Form 424B5 filed by Annovis Bio Inc.424B5 - Annovis Bio, Inc. (0001477845) (Filer)
- PRAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsMALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying wa
- SECSEC Form 10-Q filed by Annovis Bio Inc.10-Q - Annovis Bio, Inc. (0001477845) (Filer)
- SECAnnovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Annovis Bio, Inc. (0001477845) (Filer)
- PRAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial ResultsPhase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028 MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and
- PRAnnovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026. Presentation Details: Title: "The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept"Presenter: Maria Maccecchini, Ph.D., President and CEODate: Wednesday, May 13, 2026Time
- SECSEC Form DEFA14A filed by Annovis Bio Inc.DEFA14A - Annovis Bio, Inc. (0001477845) (Filer)
- SECSEC Form DEF 14A filed by Annovis Bio Inc.DEF 14A - Annovis Bio, Inc. (0001477845) (Filer)
- PRAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioBuntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in ApoE4 carriersPhase 2/3 findings support ongoing pivotal Phase 3 study in early AD, with 80% patients enrolled to date MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a new publication titled "Buntanet
ANVS FAQ
7 questionsWhat does Annovis Bio Inc. do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based...Where does ANVS stock trade?
Annovis Bio Inc. (ANVS) is listed on AMEX.What sector and industry is ANVS in?
Annovis Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Annovis Bio Inc. go public?
Annovis Bio Inc. (ANVS) completed its IPO in 2020.What are analysts saying about ANVS?
Annovis Bio Inc. has had 5 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $800.00 price target on 2026-07-08. Recent price targets range from $800.00 to $3600.00.What companies are similar to ANVS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANVS side-by-side with any of them on Quantisnow.How can I track ANVS on Quantisnow?
Quantisnow aggregates Annovis Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANVS to receive live email and push alerts on every new disclosure.